Published in Diabetes Week, July 11th, 2005
New data from a second study (SIR) show that Galida significantly and dose-dependently improves postprandial glucose and lipid metabolism in non-diabetic subjects with manifestations of insulin resistance. phase III studies for Galida are ongoing.
Historically, the treatment of type 2 diabetes has been glucocentric with little or no...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.